Clinical Trial Update: Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab and bevacizumab in patients with recurrent, persistent, or metastatic cervical cancer; results available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Cervical Cancer
• Cervical Squamous Cell Carcinoma Not Otherwise Specified

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-02-21